News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eisai Company, Ltd. (ESALY.PK) Submits Application For Proton Pump Inhibitor Pariet In Japan


12/10/2013 10:54:56 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Tokyo, Nov 28, 2013 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has submitted an application for the proton pump inhibitor Pariet (rabeprazole sodium, "rabeprazole") in Japan seeking a further indication expansion for use in the prevention of recurrent gastric or duodenal ulcer caused by low-dose aspirin therapy and the approval of a new 5 mg tablet formulation.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES